Top

Published in:

Open Access 01-10-2007 | Original Paper

Dietary fat and risk of colon and rectal cancer with aberrant MLH1 expression, APC or KRAS genes

Authors: Matty P. Weijenberg, Margreet Lüchtenborg, Anton F. P. M. de Goeij, Mirian Brink, Goos N. P. van Muijen, Adriaan P. de Bruïne, R. Alexandra Goldbohm, Piet A. van den Brandt

Published in: Cancer Causes & Control | Issue 8/2007

Abstract

Objective

To investigate baseline fat intake and the risk of colon and rectal tumors lacking MLH1 (mutL homolog 1, colon cancer, nonpolyposis type 2) repair gene expression and harboring mutations in the APC (adenomatous polyposis coli) tumor suppressor gene and in the KRAS (v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) oncogene.

Methods

After 7.3 years of follow-up of the Netherlands Cohort Study (n = 120,852), adjusted incidence rate ratios (RR) and 95% confidence intervals (CI) were computed, based on 401 colon and 130 rectal cancer patients.

Results

Total, saturated and monounsaturated fat were not associated with the risk of colon or rectal cancer, or different molecular subgroups. There was also no association between polyunsaturated fat and the risk of overall or subgroups of rectal cancer. Linoleic acid, the most abundant polyunsaturated fatty acid in the diet, was associated with increased risk of colon tumors with only a KRAS mutation and no additional truncating APC mutation or lack of MLH1 expression (RR = 1.41, 95% CI 1.18–1.69 for one standard deviation (i.e., 7.5 g/day) increase in intake, p-trend over the quartiles of intake <0.001). Linoleic acid intake was not associated with risk of colon tumors without any of the gene defects, or with tumors harboring aberrations in either MLH1 or APC.

Conclusion

Linoleic acid intake is associated with colon tumors with an aberrant KRAS gene, but an intact APC gene and MLH1 expression, suggesting a unique etiology of tumors with specific genetic aberrations.

Woutersen RA, Appel MJ, van Garderen-Hoetmer A, Wijnands MV (1999) Dietary fat and carcinogenesis. Mutat Res 443(1–2):111–127PubMed

Potter JD (1996) Nutrition and colorectal cancer. Cancer Causes Control 7(1):127–146PubMedCrossRef

Willett WC (2000) Diet and cancer. Oncologist 5(5):393–404PubMedCrossRef

Lin J, Zhang SM, Cook NR, Lee IM, Buring JE (2004) Dietary fat and fatty acids and risk of colorectal cancer in women. Am J Epidemiol 160(10):1011–1022PubMedCrossRef

Sanderson P, Johnson IT, Mathers JC, Powers HJ, Downes CS, McGlynn AP, et al (2004) Emerging diet-related surrogate end points for colorectal cancer: UK Food Standards Agency diet and colonic health workshop report. Br J Nutr 91(2):315–323PubMedCrossRef

Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M et al (1988) Genetic alterations during colorectal-tumor development. N Engl J Med 319(9):525–532PubMedCrossRef

Gryfe R, Swallow C, Bapat B, Redston M, Gallinger S, Couture J (1997) Molecular biology of colorectal cancer. Curr Probl Cancer 21(5):233–300PubMedCrossRef

Fodde R, Smits R, Clevers H (2001) APC, signal transduction and genetic instability in colorectal cancer. Nat Rev Cancer 1(1):55–67PubMedCrossRef

Kuismanen SA, Holmberg MT, Salovaara R, de la Chapelle A, Peltomaki P (2000) Genetic and epigenetic modification of MLH1 accounts for a major share of microsatellite-unstable colorectal cancers. Am J Pathol 156(5):1773–1779PubMed

10.

Breivik J, Gaudernack G (1999) Carcinogenesis and natural selection: a new perspective to the genetics and epigenetics of colorectal cancer. Adv Cancer Res 76:187–212PubMedCrossRef

11.

Lengauer C, Kinzler KW, Vogelstein B (1997) Genetic instability in colorectal cancers. Nature 386(6625):623–627PubMedCrossRef

12.

Shih IM, Zhou W, Goodman SN, Lengauer C, Kinzler KW, Vogelstein B (2001) Evidence that genetic instability occurs at an early stage of colorectal tumorigenesis. Cancer Res 61(3):818–822PubMed

13.

Smith G, Carey FA, Beattie J, Wilkie MJ, Lightfoot TJ, Coxhead J et al (2002) Mutations in APC, Kirsten-ras, and p53-alternative genetic pathways to colorectal cancer. Proc Natl Acad Sci U S A 99(14):9433–9438PubMedCrossRef

14.

Luchtenborg M, Weijenberg MP, Wark PA, Saritas AM, Roemen GM, van Muijen GN et al (2005) Mutations in APC, CTNNB1 and K-ras genes and expression of hMLH1 in sporadic colorectal carcinomas from the Netherlands Cohort Study. BMC Cancer 5:160PubMedCrossRef

15.

Fearon ER, Vogelstein B (1990) A genetic model for colorectal tumorigenesis. Cell 61(5):759–767PubMedCrossRef

16.

Breivik J, Gaudernack G (1999) Genomic instability, DNA methylation, and natural selection in colorectal carcinogenesis. Semin Cancer Biol 9(4):245–254PubMedCrossRef

17.

Bardelli A, Cahill DP, Lederer G, Speicher MR, Kinzler KW, Vogelstein B et al (2001) Carcinogen-specific induction of genetic instability. Proc Natl Acad Sci USA 98(10):5770–5775PubMedCrossRef

18.

Marnett LJ (2002) Oxy radicals, lipid peroxidation and DNA damage. Toxicology 181–182:219–222PubMedCrossRef

19.

Niedernhofer LJ, Daniels JS, Rouzer CA, Greene RE, Marnett LJ (2003) Malondialdehyde, a product of lipid peroxidation, is mutagenic in human cells. J Biol Chem 278(33):31426–31433PubMedCrossRef

20.

Leuratti C, Watson MA, Deag EJ, Welch A, Singh R, Gottschalg E, et al (2002) Detection of malondialdehyde DNA adducts in human colorectal mucosa: relationship with diet and the presence of adenomas. Cancer Epidemiol Biomarkers Prev 11(3):267–273PubMed

21.

Hendrickse CW, Kelly RW, Radley S, Donovan IA, Keighley MR, Neoptolemos JP (1994) Lipid peroxidation and prostaglandins in colorectal cancer. Br J Surg 81(8):1219–1223PubMedCrossRef

22.

Brink M, Weijenberg MP, De Goeij AF, Schouten LJ, Koedijk FD, Roemen GM et al (2004) Fat and K-ras mutations in sporadic colorectal cancer in The Netherlands Cohort Study. Carcinogenesis 25(9):1619–1628PubMedCrossRef

23.

van den Brandt PA, Goldbohm RA, van’t Veer P, Volovics A, Hermus RJ, Sturmans F (1990) A large-scale prospective cohort study on diet and cancer in The Netherlands. J Clin Epidemiol 43(3):285–295PubMedCrossRef

24.

Van den Brandt PA, Schouten LJ, Goldbohm RA, Dorant E, Hunen PM (1990) Development of a record linkage protocol for use in the Dutch cancer registry for epidemiological research. Int J Epidemiol 19(3):553–558PubMedCrossRef

25.

Luchtenborg M, Weijenberg MP, Roemen GM, de Bruine AP, van den Brandt PA, Lentjes MH et al (2004) APC mutations in sporadic colorectal carcinomas from The Netherlands Cohort Study. Carcinogenesis 25(7):1219–1226PubMedCrossRef

26.

Rowan AJ, Lamlum H, Ilyas M, Wheeler J, Straub J, Papadopoulou A et al (2000) APC mutations in sporadic colorectal tumors: A mutational “hotspot” and interdependence of the “two hits”. Proc Natl Acad Sci USA 97(7):3352–3357PubMedCrossRef

27.

Brink M, de Goeij AF, Weijenberg MP, Roemen GM, Lentjes MH, Pachen MM et al (2003) K-ras oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort Study. Carcinogenesis 24(4):703–710PubMedCrossRef

28.

Nevo table (1987) Dutch food composition table 1986–1986

29.

Goldbohm RA, van den Brandt PA, Brants HA, van’t Veer P, Al M, Sturmans F et al (1994) Validation of a dietary questionnaire used in a large-scale prospective cohort study on diet and cancer. Eur J Clin Nutr 48(4):253–265PubMed

30.

van Poppel G (1998) Intake of trans fatty acids in western Europe: the TRANSFAIR study. Lancet 351(9109):1099PubMed

31.

Willett W (1998) Nutritional epidemiology. Oxford University Press, New York

32.

Lin DY, Wei LJ (1989) The robust inference for the Cox proportional hazards model. JASA 84(408):1074–1078

33.

Wei EK, Giovannucci E, Wu K, Rosner B, Fuchs CS, Willett WC et al (2004) Comparison of risk factors for colon and rectal cancer. Int J Cancer 108(3):433–442PubMedCrossRef

34.

Schoenfeld D (1982) Partial residuals for the proportional hazards regression models. Biometrika 69(1):239–241CrossRef

35.

Bautista D, Obrador A, Moreno V, Cabeza E, Canet R, Benito E et al (1997) Ki-ras mutation modifies the protective effect of dietary monounsaturated fat and calcium on sporadic colorectal cancer. Cancer Epidemiol Biomarkers Prev 6(1):57–61PubMed

36.

Diergaarde B, Braam H, van Muijen GN, Ligtenberg MJ, Kok FJ, Kampman E (2003) Dietary factors and microsatellite instability in sporadic colon carcinomas. Cancer Epidemiol Biomarkers Prev 12(11 Pt 1):1130–1136PubMed

37.

Diergaarde B, Tiemersma EW, Braam H, Van Muijen GN, Nagengast FM, Kok FJ et al (2005) Dietary factors and truncating APC mutations in sporadic colorectal adenomas. Int J Cancer 113(1):126–132PubMedCrossRef

38.

Diergaarde B, van Geloof WL, van Muijen GN, Kok FJ, Kampman E (2003) Dietary factors and the occurrence of truncating APC mutations in sporadic colon carcinomas: a Dutch population-based study. Carcinogenesis 24(2):283–290PubMedCrossRef

39.

Kampman E, Voskuil DW, van Kraats AA, Balder HF, van Muijen GN, Goldbohm RA et al (2000) Animal products and K-ras codon 12 and 13 mutations in colon carcinomas. Carcinogenesis 21(2):307–309PubMedCrossRef

40.

Martinez ME, Maltzman T, Marshall JR, Einspahr J, Reid ME, Sampliner R et al (1999) Risk factors for Ki-ras protooncogene mutation in sporadic colorectal adenomas. Cancer Res 59(20):5181–5185PubMed

41.

Slattery ML, Curtin K, Anderson K, Ma KN, Edwards S, Leppert M et al (2000) Associations between dietary intake and Ki-ras mutations in colon tumors: a population-based study. Cancer Res 60(24):6935–6941PubMed

42.

Wark PA, Van der Kuil W, Ploemacher J, Van Muijen GN, Mulder CJ, Weijenberg MP et al (2006) Diet, lifestyle and risk of K-ras mutation-positive and -negative colorectal adenomas. Int J Cancer 119(2):398–405PubMedCrossRef

43.

Slattery ML, Anderson K, Curtin K, Ma KN, Schaffer D, Samowitz W (2001) Dietary intake and microsatellite instability in colon tumors. Int J Cancer 93(4):601–607PubMedCrossRef

44.

Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD et al (2006) The consensus coding sequences of human breast and colorectal cancers. Science 314(5797):268–274PubMedCrossRef

Title: Dietary fat and risk of colon and rectal cancer with aberrant MLH1 expression, APC or KRAS genes
Authors: Matty P. Weijenberg
Margreet Lüchtenborg
Anton F. P. M. de Goeij
Mirian Brink
Goos N. P. van Muijen
Adriaan P. de Bruïne
R. Alexandra Goldbohm
Piet A. van den Brandt
Publication date: 01-10-2007
Publisher: Kluwer Academic Publishers
Published in: Cancer Causes & Control / Issue 8/2007
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI: https://doi.org/10.1007/s10552-007-9032-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 8/2007

Occupation and keratinocyte cancer risk: a population-based case–control study

The effect of atopy, childhood crowding, and other immune-related factors on non-Hodgkin lymphoma risk

Reduced lung cancer deaths attributable to decreased tobacco use in Massachusetts

Health behaviors of cancer survivors: data from an Australian population-based survey

Consumption of soy foods and the risk of breast cancer: findings from the Japan Collaborative Cohort (JACC) Study

Dietary carbohydrate, glycemic index, and glycemic load and the risk of colorectal cancer in the BCDDP cohort

Keynote webinar | Spotlight on antibody–drug conjugates in cancer